News

New clinical study shows Novaliq NovaTears® +Omega-3 eye drops is significantly effective treatment for dry eye disease.

NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.

Read More

Maxigesic® Oral Liquid gets first regulatory approval

Maxigesic Oral Liquid – a non-opioid analgesic developed for children – achieves first approval in Europe to set up the first global launch and a pathway for further registrations and launches.

Read More

AFT at APP 2021

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.

Read More

AFT extends Maxigesic® IV license in South America

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the medicine’s addressable market in Latin America and the Caribbean to 17 countries.

Read More

AFT licenses Maxigesic® IV in the US

AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.

Read More

AFT licenses Pascomer for Europe

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®

Read More

Maxigesic® IV licensed in eight new European markets

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets.

Read More

AFT confirms demonstration of 24-hour efficacy for Crystawash extend hand sanitiser

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser

Read More

AFT builds North American momentum

Diversified pharmaceutical company appoints new north American-based director and launches Maxigesic® in Canada.

Read More

Management financial discussion and analysis for the half year to 30 September 2020

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio

Read More

Financial results for half year ended 30 September 2020

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio.

Read More

AFT opening European office, signs new partners for maxigesic iv and oral range

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces the establishment of a new subsidiary in Ireland

Read More